Search

Crowding and other strong predictors of upper respiratory tract carriage of otitis media-related bacteria

Streptococcus pneumoniae, Moraxella catarrhalis, and nontypeable Haemophilus influenzae is associated with otitis media

A retrospective population-based cohort study identifying target areas for prevention of acute lower respiratory infections in children

Acute lower respiratory infections (ALRI) are a major cause of hospitalisation in young children

Project helps Ethan belong

Ethan recently took part in Belong, a study led by The Kids which aims to ensure deaf and hard of hearing kids have a happy & positive school experience

Cochrane CSOM: A suite of reviews examining the effectiveness of interventions to treat chronic suppurative otitis media (CSOM) globally

Chris Peter Brennan-Jones Richmond PhD MBBS MRCP(UK) FRACP Head, Ear and Hearing Health Head, Vaccine Trials Group chris.brennan-jones@thekids.org.au

Ear Explorers: A ‘real-life research project’ enabling children to view inside their own ears using smartphone video-otoscopy

Chris Brennan-Jones PhD Head, Ear and Hearing Health chris.brennan-jones@thekids.org.au Head, Ear and Hearing Health Professor Chris Brennan-Jones is

Ear Portal: An ENT and Audiology referral portal for improving access to ear health services for children using telehealth

Chris Deborah Peter Tanisha Greta Karina Brennan-Jones Lehmann Richmond Cayley Bernabei Tao PhD AO, MBBS, MSc MBBS MRCP(UK) FRACP BBiomed (Hons) BSc

Koorlungkas yarning: Exploring the impact of OM on early language and communication skills in urban Aboriginal families

Deborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

“You’re telling us to go first?!” COVID-19 pandemic and vaccination experiences among Aboriginal adults in Western Australia

Globally, Indigenous populations have been disproportionately impacted by pandemics. In Australia, though national infection rates with COVID-19 infections in Aboriginal and/or Torres Strait Islander people were lower in the first 12 months of the COVID-19 pandemic, there was soon a greater burden in Aboriginal and/or Torres Strait Island people once Omicron was circulating. Uptake of the COVID-19 vaccine was also lower among Aboriginal and/or Torres Strait Islander people.

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.